Liabilities / Assets
16th percentile
Tied with the lowest-debt nonprofits in its peer group.
Oxfendazole Development Group
990 • Fiscal year 2023 • EIN 81-1547477
Siviq Scores
Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.
0.00x
Liabilities / Revenue
16th percentile
Tied with the lowest-debt nonprofits in its peer group.
Net Margin
1st percentile
Higher net margin than 1% of similar nonprofits.
Top Officer Pay
Score unavailable
This filing does not contain officer compensation rows.
Asset Growth
3rd percentile
Faster asset growth than 3% of similar nonprofits.
Revenue Growth
1st percentile
Faster revenue growth than 1% of similar nonprofits.
Balance Sheet
Assets
Down$1,146,889
Down $575,020 (-33%) from 2022
Net Assets
Down$1,146,889
Down $557,493 (-33%) from 2022
Liabilities
Down$0
Down $17,527 (-100%) from 2022
Revenue And Expenses
Revenue
Down$58,517
Down $1,651,610 (-97%) from 2022
Expenses
Up$604,664
Up $562,050 (+1319%) from 2022
Net Income
Down-$546,147
Down $2,213,660 (-133%) from 2022
Historical Trend
Filing Detail Status
This 2023 filing currently has summary financial data only. Detailed schedules, leadership, and program rows are not available for this filing yet.
Jump To
Filing Snapshot
- Filing Period
- Jan 1, 2023 to Dec 31, 2023
Mission and Program Overview
Mission
The Oxfendazole Development Group is a 501c3 nonprofit organization formed and operated exclusively for charitable purposes specifically for the purpose of engaging in research and development of pharmaceutical treatments to help eliminate neglected tropical diseases NTDs and to facilitate access to such treatments for individuals in need.
Document Assets
No mirrored PDF or thumbnail assets are attached yet.
Filings
Displayed year
2023 • Form 990Summary only. Only limited summary data is available for this year.
- Assets
- $1,146,889
- Liabilities
- $0
- Net assets
- $1,146,889
- Revenue
- $58,517
- Expenses
- $604,664
- Net income
- -$546,147